Company Description
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer.
In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;.
It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC.
The company was founded in 1956 and is based in Bedford, Massachusetts.
| Country | United States |
| Founded | 1956 |
| IPO Date | Jun 25, 2015 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 834 |
| CEO | Brian Markison |
Contact Details
Address: 201 Burlington Road, South Building Bedford, Massachusetts 01730 United States | |
| Phone | 978 671 8001 |
| Website | lantheus.com |
Stock Details
| Ticker Symbol | LNTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001521036 |
| CUSIP Number | 516544103 |
| ISIN Number | US5165441032 |
| Employer ID | 35-2318913 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Brian A. Markison | Chief Executive Officer and Director |
| Paul M. Blanchfield | President |
| Robert J. Marshall Jr., CFA | Chief Financial Officer and Treasurer |
| Dr. Jean-Claude Provost M.D. | Chief Science Officer |
| Daniel M. Niedzwiecki | Chief Administrative Officer, General Counsel and Corporate Secretary |
| Kimberly Brown | Chief Accounting Officer |
| Dorothy Barr | Senior Vice President of Manufacturing and Technical Operations |
| Lee Anne Howe | Chief Information Officer |
| Mark Richard Kinarney | Senior Director of Investor Relations |
| Linda S. Lennox | Vice President of Corporate Communications and Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 144 | Filing |
| Nov 8, 2024 | 144 | Filing |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 144 | Filing |
| Sep 25, 2024 | 8-K | Current Report |